Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company’s products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale up; assay development services; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
Name | Title | Since | Age |
|---|---|---|---|
| Wilber Huang | Chairman | - | - |
| Peiru Ji | GM & Director | - | - |
| Anna Cha | Independent Director | - | - |
| Jin Jun Su | Independent Director | - | - |
| Shao De Ye | Independent Director | - | - |
| Yuehong Chen | Director | - | - |
| Qijing Qiu | Director | - | - |
| Shi Ming Yang | Supervisor | - | - |